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Abstract: The potential of marine benthic cyanobacteria as a source of anticancer drug 
candidates was assessed in a screen for induction of cell death (apoptosis) in acute myeloid 
leukemia (AML) cells. Of the 41 marine cyanobacterial strains screened, more than half 
contained cell death-inducing activity. Several strains contained activity against AML cells, 
but not against non-malignant cells like hepatocytes and cardiomyoblasts. The apoptotic 
cell death induced by the various strains could be distinguished by the role of caspase 
activation and sensitivity to the recently detected chemotherapy-resistance-associated 
prosurvival protein LEDGF/p75. One strain (M44) was particularly promising since its 
activity counteracted the protective effect of LEDGF/p75 overexpressed in AML cells, 
acted synergistically with the anthracycline anticancer drug daunorubicin in AML cells, and 
protected cardiomyoblasts against the toxic effect of anthracyclines. We conclude that 
culturable benthic marine cyanobacteria from temperate environments provide a promising 
and hitherto underexploited source for novel antileukemic drugs.  
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1. Introduction 
Marine cyanobacteria have been recognized as a source for new drugs and drug leads [1,2]. For 
instance, clinical anticancer trials are being conducted with soblidotin (TZT-1027) and synthadotin 
(ILX-651), two derivatives of dolastatin 10 isolated from the benthic tropical marine cyanobacteria 
Symploca sp. [3,4]. In addition, derivatives of curacin A isolated from the benthic tropical marine 
cyanobacteria Lyngbya majuscula are in preclinical trials for treatment of cancer [5]. Most cytotoxic 
marine cyanobacterial compounds have been isolated from tropical benthic Lyngbya sp. and Symploca 
sp. forming large mats, whereas only a few cytotoxic compounds have been reported from other marine 
genera [1,2,6]. Less studied marine cyanobacteria genera should therefore be included in  
anticancer screens.  
Acute myeloid leukemia (AML) is the second most common form of leukemia [7]. Treatment of 
AML consists mainly of chemotherapy using cytosine arabinoside (Ara-C) and the anthracycline 
daunorubicin [8]. Chemoresistant disease, either as primary resistance to induction therapy or as 
relapse due to resistant residual disease, is the major cause of treatment failure in most cancers, 
including AML [9,10]. There are several recently discovered factors involved in chemoresistance. 
Increased expression of the transcriptional co-activator Lens Epithelium-Derived Growth Factor 
LEDGF/p75 has been reported in chemotherapy-resistant human AML blasts as well as in breast and 
bladder carcinomas [11–13]. Another anti-apoptotic protein that confers chemotherapy resistance to 
AML cells, and is associated with a poor therapeutic prognosis, is Bcl-2 [14,15]. There is a need for 
new therapies in treatment of AML, since if standard therapy fails there is usually no alternative 
treatment [9,10]. New therapies are also needed for other types of cancer, and drugs used to treat 
leukemia have often been transferred to other cancers with little or no modifications, as exemplified by 
the anthracyclines [16]. 
We have previously shown that cyanobacteria constitute a rich source of bioactivities [17–21], and 
wanted to investigate if culturable marine benthic cyanobacteria from temperate environments were 
potential producers of compounds with anticancer potential. We investigated strains sampled from the 
shores of the Baltic Sea and found that a high proportion of these induced cell death in AML cells. 
Three strains were able to induce apoptosis in chemoresistant AML cells with enforced expression of 
LEDGF/p75, whereas non-malignant cells remained viable. In combination with daunorubicin these 
three anti-AML activities induced an apoptotic synergistic response in leukemia cells, but not in 
cardiomyoblasts. 
2. Results 
2.1. Screening of benthic marine cyanobacteria for leukemia cell death inducers 
Forty-one benthic Baltic Sea cyanobacterial strains of the genera Anabaena, Nostoc, Calothrix and 
Cyanothece (Table S1 and Figure S1), previously screened for death-inducing activity against primary 
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hepatocytes [17], were extracted sequentially with water, aqueous 70% methanol, and 1:1 
methanol:dichloromethane (A, B and C extracts, respectively). They were first screened for cell  
death-inducing activity against the AML cell line IPC-81wt [22], which originates from the BNML rat 
model, known to be a reliable predictor of the outcome of anticancer treatment [23]. Nineteen A 
extracts, 13 B extracts, and 6 C extracts contained cell death inducers. Ten strains (M4, 8, 9, 11, 12, 13, 
23, 26, 33, 37) contained cell death inducing activity in more than one extract, like strain M26 that 
contained activity in the A and C extract, but not in the intermediate B extract (Figure 1). Several of the 
extracts with anti-AML activity, most notably the A extracts from the Anabaena sp. M4, M27, M30, 
M44 and M45 (Figure 1), were previously found to lack activity against normal primary hepatocytes 
(see [17]). We therefore conclude that marine benthic cyanobacteria are not only a rich source of cell 
death inducing activity, but also contain apoptogens selective for AML cells.  
Figure 1. Induction of leukemia cell death by cyanobacterial extracts. Rat acute myeloid 
leukemia cells were incubated with aqueous (A), aqueous methanol (B) or  
methanol-dichloromethane (C) cyanobacterial extracts at a concentration of 4 mg DW 
biomass/mL for 18 hours before being fixed in 2% buffered formaldehyde (pH 7.4) with 
the DNA-dye Hoechst 33342. Cell death was assessed by microscopic assessment of 
surface and nuclear morphology. The results are the mean, n = 3. Vehicle treated cells had 
less than 2% apoptosis.  
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2.2. Modulation of blood platelet activity by cyanobacterial extracts 
Thrombocyte function is critical in leukemia, which is characterized by platelet deficiency due both 
to thrombocytopenia and thromboembolic complications [8,24,25]. Moreover, treatment of leukemia 
with cytotoxic drugs may change platelet function in vivo (reviewed in [26]). We therefore studied if 
any of the cyanobacterial extracts contained blood platelet activating activity that could limit 
usefulness as anti-AML agents. Interestingly, we found that a high proportion of the C extracts 
contained blood platelet activators (Figure 2). Of more importance for the present study is that the 
antileukemic A extracts of M27, M30, M44 and M45, unlike the anticancer drug daunorubicin [26], 
lacked platelet-modulating activity (Figure 2A). 
Figure 2. Modulation of blood platelet activity by cyanobacterial extracts. Gel-filtered 
human blood platelets were incubated for 30 min with PE-conjugated anti-CD62P and 
aqueous (A), aqueous methanol (B) or methanol-dichloromethane (C) cyanobacterial 
extracts, 4 mg DW biomass/mL, or thrombin receptor agonist peptide (TRAP). The 
platelets were then fixed and analyzed for externalization of CD62P by flow cytometry. 
The results are mean and SEM, n = 3–9. 
 
2.3. Drug-relevant features of the apoptogens in cyanobacteria M27, M30 and M44 
Although the IPC-81 AML cells used in the primary screen respond in a clinically relevant way to 
present day anti-leukemic drugs both in vivo and in vitro [23,27], it is important to know if the  
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IPC-81 apoptogens induce death in other relevant AML cell lines. In this respect, the aqueous extracts 
from M27, M30 and M44 were overall more efficient than those from M45 and M4 (not shown). M27, 
M30 and M44 induced apoptosis rapidly in human HL-60 AML cells (Figure 3), even compared to a 
higher-than-therapeutic concentration of daunorubicin in these cells ([27], data not shown). The high 
potency and rapid action of M27, M30 and M44 towards the leukemia cells are advantageous for in 
vivo therapy, since there will be a shorter burst of the drug, thus allowing less time for the formation of 
potentially generally harmful metabolites of the drug. For these reasons, the aqueous extracts from 
M27, M30 and M44 were selected for further studies. 
Figure 3. Cyanobacterial extracts induced rapid apoptosis in HL-60 acute myeloid leukemia 
cells. HL-60 cells were incubated without (Ctr) or with 4 mg DW biomass/mL of aqueous 
cyanobacterial extracts for 30, 60 or 120 min. Cells were fixed and stained, and apoptosis 
assessed as described in the legend to Figure 1. The results are mean and SEM, n = 3. 
 
Cell death induced by M27, M30 or M44 had the morphological hallmarks of apoptosis, such as 
chromatin condensation, nuclear fragmentation, surface budding and shedding of apoptotic bodies 
(Figure 4A-D). The apoptotic phenotype was as striking as the one observed in cells incubated with the 
benchmark anti-AML drug daunorubicin (Figure 4E).  
Cells overexpressing Bcl-2 are resistant towards stimuli leading to mitochondrial instability with 
release of pro-apoptotic proteins [28]. IPC-81 AML cells with enforced expression of Bcl-2 [29] were 
resistant towards apoptosis induced by either daunorubicin or by the apoptogens in M27, M30 or M44 
(not shown). This indicates that like daunorubicin, the cyanobacterial apoptogens signaled through the 
mitochondrial cell death pathway. Significant differences were discovered, however, between the AML 
apoptogens with respect to the involvement of caspase dependent cell death pathways. The apoptosis 
induced by activation of the cAMP-dependent protein kinase by a cAMP analogue was completely 
abrogated by the caspase inhibitor zVADfmk, whereas apoptosis induced by M30 or M44 appeared to 
be caspase independent and apoptosis induced by daunorubicin or M27 was partially inhibited by the 
caspase inhibitor (Figure 5A).  
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Figure 4. Apoptotic morphology induced by cyanobacterial extracts in AML cells. Rat 
leukemia cells (A: control) were added the aqueous extract of the cyanobacterial strain M27 
(B), M30 (C), M44 (D) or 50 nM daunorubicin (DNR, E) as described in the legend to 
Figure 1, and photomicrographs were taken using differential interference contrast (upper) 
and UV (lower). Bar represent 10 m.  
 
Figure 5. Involvement of caspases and LEDGF/p75 in apoptosis induced by cyanobacterial 
extracts. (A) Rat acute myeloid leukemia cells were incubated with or without 50M of the  
pan-caspase inhibitor zVAD for 30 min before addition of 200 nM daunorubicin (DNR),  
25 M 8-chlorophenylthio-cAMP (8-CPT), or 4 mg DW biomass/mL of cyanobacterial 
extracts. The experiments were stopped after 7 h of incubation. zVAD-fmk alone induced 
less than 3% apoptosis during the 7.5 h of incubation. (B) Rat acute myeloid leukemia cells 
with or without enforced expression of the survival factor LEDGF/p75 (black and white 
columns, respectively) were incubated with various concentrations of known apoptosis-
inducers or cyanobacterial extracts for 18 hours. The cells were fixed and stained, and 
apoptosis assessed as described in the legend to Figure 1. The results are mean and SEM,  
n = 3–6.  
 
Drug resistance is the major cause of therapeutic failure in AML [9,10]. We have found that 
LEDGF/p75 is consistently upregulated in AML blasts from patients with chemoresistant AML [11]. 
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LEDGF/p75 is a survival factor reported to inhibit a caspase-independent lysosomal cell death  
pathway [13]. As previously observed [11], we found, that IPC-81 cells with enforced expression of 
LEDGF/p75 were less sensitive towards apoptosis induced by either cAMP analog or daunorubicin. In 
contrast, such cells had intact sensitivity towards M44, and even showed enhanced apoptosis, 
compared to wild-type cells, at low M44 concentrations (Figure 5B). M27 and M30 induced a response 
intermediate between M44 and daunorubicin. They resembled M44 by tending to enhance apoptosis in 
the LEDGF/p75 overexpressing cells at low concentrations, but were like daunorubicin less efficient 
against these cells at high concentrations (Figure 5B). We conclude that M44 and to a lesser extent 
M27 and M30 had better ability than daunorubicin to circumvent the chemoresistance provided by 
LEDGF/p75.  
Figure 6. Cyanobacterial extracts induce a synergistic apoptotic response with 
daunorubicin in acute myeloid leukemia cells, but not in cardiomyoblasts. Rat acute 
myeloid leukemia cells without (A) or with enforced expression of the survival factor 
LEDGF/p75 (B), or cardiomyoblasts (C), were incubated for 18 hours with cyanobacterial 
extracts alone or in combination with daunorubicin (DNR) (white and black columns, 
respectively) before fixation, staining and assessment of apoptosis as described in the 
legend to Figure 1. The results are mean and SEM, n = 3. 
 
Mar. Drugs 2010, 8                   
 
 
2666 
Since M44, and to a lesser extent M27 and M30, differed from daunorubicin in cell death 
mechanism and in efficiency against LEDGF/p75 overexpressing cells, they could be useful adjuncts to 
daunorubicin. In fact, all three synergized strongly with daunorubicin to induce apoptosis whether the 
AML cells had enforced expression of LEGDF/p75 or not (Figure 6A and B). This suggests that the 
cyanobacterial apoptogens have potential to enhance the efficiency of daunorubicin, also in cells 
expressing the chemoresistance-associated LEDGF/p75.  
A major limitation for drugs and drug combinations is unwanted side effects [10,16]. Since the 
major side effect of anthracyclines in cancer therapy is cardiotoxicity [8,16], we studied whether any of 
the cyanobacterial activities had intrinsic cardiomyoblast toxicity or enhanced the toxicity of 
daunorubicin in such cells. The intrinsic ability of M27, M30 or M44 to induce cardiomyoblast death 
was far lower than for the AML cells, confirming their AML selectivity (Figure 6 and data not shown). 
Furthermore, at concentrations effective against AML cells, M27, M30 and M44 failed to enhance the 
daunorubicin toxicity towards cardiomyoblasts. On the contrary, M44 significantly reduced the 
daunorubicin toxicity (Figure 6C).  
3. Discussion 
We have previously reported that cyanobacteria from temperate environments are a rich source of 
bioactivities [17–21]. In the present study we have shown that culturable marine benthic cyanobacteria 
from temperate environments produce bioactive compounds with potential as anticancer drugs. In line 
with previous studies [17,20,21], we found that cyanobacteria of the genera Anabaena most frequently 
contained bioactivities. 
Based on the initial screen we focused on the five aqueous cyanobacterial extracts, which induced 
apoptosis preferentially in AML cells (Figure 1), whereas normal primary hepatocytes remained viable 
[17]. Three of them (M30, M27 and M44) induced apoptosis in human AML cells in less than two 
hours, suggesting an efficient and direct cell death pathway. The rapid action is an advantage from a 
pharmaceutical standpoint, especially if the active compounds should have short biological half-life, 
whether due to renal excretion or metabolic conversion to inactive metabolites. 
As based on defining morphological criteria [30], the cyanobacteria induced classical apoptotic cell 
death (Figure 4). The death depended little or not at all on caspases (Figure 5A). From a drug point of 
view it is interesting that the apoptogenic activity in M27, M30 and M44 was high also against AML 
cells with enforced expression of LEDGF/p75 (Figure 6B), which is upregulated in most cases of 
chemotherapy-resistant AML [11]. 
It is recommended that new AML treatment strategies should consist of drug combinations [10] to 
cover a broader range of cell death pathways, since acquired apoptotic resistance caused by 
deregulation of death signaling mechanisms is a common feature in malignant cells [31]. If two 
compounds act synergistically their combination may allow lower doses of each and thereby decrease 
the toxicity as compared to monotherapy. We found that the combination of a moderate concentration 
of the anticancer drug daunorubicin with M27, M30 or M44 (Figure 6A) induced a synergistic 
apoptotic response in AML cells (Figure 6A) and chemoresistant AML cells with enforced expression 
of LEDGF/p75 (Figure 6B). This means that these cyanobacterial apoptogens have the ability to greatly 
improve the therapeutic index of daunorubicin. A severe side effect of anthracycline therapy is 
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cardiotoxicity [8,16] and it is crucial that anticancer drug combinations do not escalate this cardiotoxic 
effect. Notably, neither of the cyanobacterial extracts synergized with daunorubicin causing 
cardiomyoblast toxicity (Figure 6C). In fact, M44 appeared to protect the cardiac cells against 
daunorubicin-induced toxicity. These properties of the cyanobacterial apoptogens are important in 
AML drug development, since less toxic treatment strategies as well as strategies to circumvent 
chemoresistance are needed [10].  
We found that the majority of the anti-AML-activity resided in the aqueous extracts. This is 
promising since high aqueous solubility is considered pharmacokinetically favorable [32,33]. On the 
other hand, highly water-soluble compounds can be difficult to isolate using high performance liquid 
chromatography, as illustrated for the death-inducing activity of M44 (supplementary Figure S2). 
Recent advances in scaled-up counter-current chromatography [34,35] and further improvements of 
large scale culturing of benthic cyanobacteria will presumably pave the way for more satisfactory large 
scale isolation of the highly polar anticancer compounds from marine benthic and other [20] 
cyanobacteria. 
4. Conclusions  
In summary, this study shows that culturable marine benthic cyanobacteria are a promising source of 
bioactive compounds with potential as anticancer drug candidates or lead compounds. The observation 
that compounds from benthic cyanobacteria combined with daunorubicin induce a synergistic apoptotic 
response in AML cells, but not in normal cardiomyoblasts supports this conclusion. The apoptogens 
contained in these marine benthic cyanobacteria, coupled to current progress in scaled-up culturing and 
chemical purification, indicate that this hitherto underexploited niche of cyanobacteria is an exploitable 
source for novel anticancer drug candidates.  
5. Experimental Section 
5.1. Materials 
Dichloromethane, dimethylsulfoxide (DMSO), Hoechst 33342, penicillin/streptomycin,  
8-chlorophenylthio-cAMP and daunorubicin were from Sigma-Aldrich (St. Louis, USA). Methanol and 
formaldehyde were from VWR (West Chester, USA). Dulbecco’s Modified Eagle Medium (DMEM), 
Fetal Calf Serum (FCS) and Horse Serum (HS) were supplied by EuroClone Life Sciences Division 
(Milan, Italy). RPMI 1640 Medium (Gibcoinvitrogen cell culture) was from Invitrogen AS 
(Carlsbad, USA). PE-conjugated anti-human CD62P antibody (CAT. #348107) was from Becton 
Dickinson Biosciences (San Jose, USA). Thrombin receptor agonist peptide (TRAP, SFLLRN) was 
from the Biotechnology centre of Oslo (Oslo, Norway). Z-val-ala-DL-asp-fluoromethylketone  
(zVAD-fmk) was from Alexis Biochemicals (San Diego, USA). 
5.2. Isolation and cultivation of cyanobacterial strains 
The cyanobacterial strains used in this study [17] were collected from sediment, sand, surface of 
stones, rocks, water plants, macroalgae, mussels or molluscs from the Baltic Sea at Porkkala (Gulf of 
Finland). Strains had previously been identified [17] based on morphology [36] as Anabaena, Nostoc, 
Mar. Drugs 2010, 8                   
 
 
2668 
Calothrix or Cyanothece (see supplementary material: Figure S1 and Table S1) and mass cultivated as 
previously described [17]. Cyanobacterial cells were cultured for 20–60 days before they were 
harvested by centrifugation and freeze dried.  
5.3. Sequential extraction of cyanobacterial biomass 
Extraction of cyanobacterial biomass was performed as described by Herfindal et al. [17]. In brief, 
freeze-dried cyanobacterial biomass was first extracted in water, followed by extraction in 70% 
aqueous methanol and finally 1:1 (v/v) methanol:dichloromethane. The extracts were then dried in a 
centrifugal vacuum concentrator (Savant SpeedVacAES1010) and resuspended in either 0.2 mL 
water (aqueous; A extract), 0.05 mL water (70% aqueous methanol; B extract) or 0.05 mL DMSO 
(methanol:dichloromethane; C extract). 
5.4. Maintenance of cell lines, experimental conditions and determination of cell death 
The rat promyeloid leukemia cell lines IPC-81 wild-type cells [22], and IPC-81 with enforced 
expression of LEDGF/p75 [11] or Bcl-2 [29], were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 50 U/mL of penicillin and 0.05 mg/mL streptomycin and 10% (v/v) heat 
inactivated horse serum. The rat cardiomyoblastic cell line H9c2 (ATCC: CRL-1446) was cultured in 
DMEM with antibiotics as described above but enriched with 10% (v/v) heat inactivated fetal calf 
serum. When the cells reached 80% confluence, they were detached by mild trypsin treatment  
(0.33 mg/mL trypsin for 5 min at 37 C), washed and reseeded in fresh medium to 25% confluence. 
The human myeloid leukemia cell line HL-60 (ATCC: CCL-240) was cultured in RPMI medium with 
antibiotics as described above and enriched with 10% (v/v) heat inactivated fetal calf serum. All cells 
were cultured at 37 C in a humid atmosphere of 5% CO2. 
For assays of cell death, the suspension cells were centrifuged at 160 × g for 4 min, resuspended in 
fresh medium and 1.5 × 10
4
 cells were seeded in 0.1 mL in a 96-well tissue culture plate. The 
cardiomyoblasts were detached, centrifuged, and 2000 cells were seeded in each well of a 96-well 
tissue culture plates 24 hours before start of the cell death assays. The experiments were stopped by 
addition of 0.1 mL PBS containing 4% formaldehyde (pH 7.4) and 0.01 mg/mL of the DNA specific 
fluorescent dye Hoechst 33342. Apoptosis was scored by differential interference contrast and 
fluorescence microscopy (Axiovert 35M, Zeiss) as previously described [37]. Untreated cells or cells 
added vehicle exhibited a viability of more than 97%.  
5.5. Isolation, incubation and flow cytometry analysis of human blood platelets. 
Isolation of human blood platelets was from fresh whole blood, as previously described [38,39]. In 
brief, platelet rich plasma obtained by centrifugation of whole blood was gel filtered and platelets 
eluted into a calcium-free Tyrode’s buffer containing glucose and bovine serum albumin at pH 7.3.  
The gel-filtered human blood platelets (3.5 × 10
7 
per sample) were incubated under non-stirring 
conditions for 30 min with cyanobacterial extract or Thrombin Receptor Agonist Peptide SFLLRN 
(TRAP), PBS (5 μL) and anti-CD62PE (0.24 g/mL) in a total volume of 25 μL. The platelets were 
then fixed 1:16 with 0.5% (v/v) paraformaldehyde in PBS and analysis of P-selectin (CD62) expression 
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was carried out using a FACSort flow cytometer as described by Selheim et al. [40]. Ten thousand 
platelets, identified by size (light scatter gating), were analyzed for CD62PE fluorescence  
per sample. 
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